Urothelial Carcinoma — Trials

Urothelial Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

623 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 236
Recruiting: 118
Ph III recruiting: 14
Growth YoY: +37.5%
Industry share: 33%
Top sponsor: National Cancer Institute (NCI)
Termination share: 44.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (99)

clinicaltrialsPublishedShowing 1–12 of 12 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06331299	A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer(UTOPIA)	active not recruiting	Phase 3	99	UroGen Pharma Ltd.INDUSTRY	7	Sep 28, 2026	clinicaltrials
NCT04579224	Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer	active not recruiting	Phase 3	184	National Cancer Institute (NCI)NIH	1	Sep 16, 2026